Brasada Capital Management LP Purchases Shares of 2,250 Becton Dickinson and Co (NYSE:BDX)

Brasada Capital Management LP purchased a new stake in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,250 shares of the medical instruments supplier’s stock, valued at approximately $569,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of BDX. Whittier Trust Co. increased its position in shares of Becton Dickinson and by 0.6% during the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after acquiring an additional 40 shares in the last quarter. ProVise Management Group LLC increased its position in shares of Becton Dickinson and by 2.2% during the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock worth $479,000 after acquiring an additional 41 shares in the last quarter. Pitcairn Co. increased its position in shares of Becton Dickinson and by 1.3% during the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock worth $813,000 after acquiring an additional 41 shares in the last quarter. Ropes Wealth Advisors LLC increased its position in shares of Becton Dickinson and by 0.6% during the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after acquiring an additional 43 shares in the last quarter. Finally, Armor Investment Advisors LLC increased its position in shares of Becton Dickinson and by 0.5% during the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock worth $2,335,000 after acquiring an additional 44 shares in the last quarter. 84.29% of the stock is owned by hedge funds and other institutional investors.

Shares of BDX stock opened at $244.79 on Friday. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $264.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19. The company has a 50-day simple moving average of $251.93 and a two-hundred day simple moving average of $246.89. The company has a market capitalization of $66.59 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.62 and a beta of 1.09.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The business had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period in the prior year, the firm posted $2.93 EPS. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, sell-side analysts forecast that Becton Dickinson and Co will post 12.58 EPS for the current fiscal year.

Several equities research analysts have recently commented on BDX shares. Piper Jaffray Companies decreased their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Wells Fargo & Co reduced their price objective on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Wednesday. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Morgan Stanley upped their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Becton Dickinson and presently has a consensus rating of “Buy” and an average target price of $266.09.

In other Becton Dickinson and news, EVP James C. Lim sold 9,299 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $263.53, for a total value of $2,450,565.47. Following the transaction, the executive vice president now directly owns 33,041 shares in the company, valued at $8,707,294.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the transaction, the senior vice president now owns 5,180 shares in the company, valued at $1,347,214.40. The disclosure for this sale can be found here. Insiders sold a total of 32,174 shares of company stock valued at $8,354,013 over the last ninety days. 0.12% of the stock is currently owned by insiders.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.